Figure S4 from Phase 1 Combination Study of the CHK1 Inhibitor Prexasertib and the PARP Inhibitor Olaparib in High-grade Serous Ovarian Cancer and Other Solid Tumors

Authors :: Geoffrey I. Shapiro
Alan D. D'Andrea
Jean-Bernard Lazaro
Kalindi Parmar
Loan Vuong
Courtney Gannon
Nicholas Quinn
Allison Powers
Jennifer Hedglin
Adrienne de Jonge
Sarah Kelland
Bose Kochupurakkal
Khanh T. Do
Publication Year :: 2023
Publisher :: American Association for Cancer Research (AACR), 2023.
Abstract: Immunohistochemical Profile Patient 21

Full Text Access

Tools